TaxTMI 
TaxTMI 
STEERLife Redefines Potent Drug Development with Clean, Green, Continuous Processing
X X X X Extracts X X X X
X X X X Extracts X X X X
....TEERLife Redefines Potent Drug Development with Clean, Green, Continuous Processing<BR>PTI News<BR>Dated:- 15-5-2025<BR>PTI<BR>As a next-gen CRDMO, driving global pharma with continuous, solvent-free tech for potent drug development BENGALURU, India, May 15, 2025 /PRNewswire/ -- STEERLife, the life sciences division of STEER World, is advancing the development and manufacturing of potent and compl....
X X X X Extracts X X X X
X X X X Extracts X X X X
....ex drug products. This initiative marks a significant advancement in a field that has long been considered one of the most challenging areas within pharmaceutical science. At the core of this advancement is STEERLife's proprietary solvent-free melt fusion technology, a continuous processing system that eliminates the need for harmful organic solvents. Designed to precisely handle high-potency an....
X X X X Extracts X X X X
X X X X Extracts X X X X
....d hard-to-develop molecules, this platform significantly enhances formulation efficiency, safety, and scalability. As a next-generation Contract Research, Development & Manufacturing Organization (CRDMO), STEERLife provides comprehensive development capabilities for complex and potent drugs - including NCEs, hormone therapies, orphan drugs, complex generics (ANDAs) and 505(b)(2) products, assist....
X X X X Extracts X X X X
X X X X Extracts X X X X
....ing global pharma in overcoming development and manufacturing challenges through process-driven innovation. "Potent drug development demands more than just compliance; it requires control, care, and innovation," said Indu Bhushan, CEO & Director at STEERLife. "Our continuous, solvent-free platform brings all of that together - enabling faster, cleaner and more scalable development for the world'....
X X X X Extracts X X X X
X X X X Extracts X X X X
....s most demanding therapies." STEERLife has already initiated the development of several key drug products set for market release from 2026 onwards. These include generic versions of ERLEADA® (Apalutamide), XTANDI® (Enzalutamide), VENCLEXTA® (Venetoclax), and LYNPARZA® (Olaparib), reflecting the company's ability to take on complex, high-barrier drug programs with confidence. Working in tande....
X X X X Extracts X X X X
X X X X Extracts X X X X
....m with partner facilities, STEERLife is strategically positioned to serve leading pharmaceutical markets across the United States, Europe, Latin America, Russia, MENA and Southeast Asia. As a company that pioneered the shift from batch to seamless continuous processing in India, STEERLife continues to lead the evolution of pharmaceutical manufacturing - empowering clients worldwide to shorten de....
X X X X Extracts X X X X
X X X X Extracts X X X X
....velopment timelines, raise quality benchmarks and unlock next-gen drug delivery. About STEERLife STEERLife, a division of STEER World, is a pioneering life sciences company transforming how pharmaceuticals are developed, manufactured, and consumed. Leveraging cutting-edge continuous processing and proprietary clean & green technologies, STEERLife enables faster, greener and more efficient drug d....
X X X X Extracts X X X X
X X X X Extracts X X X X
....evelopment. The company offers a complete spectrum of services to global partners: ranging from formulation and analytical development to technology transfer, regulatory support and commercial-scale manufacturing. Logo: (Disclaimer: The above press release comes to you under an arrangement with PRNewswire and PTI takes no editorial responsibility for the same.). PTI PWR PWR<BR> News - Press rele....
X X X X Extracts X X X X
X X X X Extracts X X X X
....ase - PIB....